Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CG200745 PPA with Gemcitabine and Erlotinib in Unresectable or Metastatic Pancreatic Cancer
KCT0002037Phase 2Recruiting
- Sponsor
- Crystal Genomics
- Start
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ivaltinostat in pancreatic adenocarcinoma (PDAC), sponsored by Crystal Genomics. Started Apr 2016; status: recruiting.
02
Drugs
ivaltinostat
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on KCT0002037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0002037.